Effects of oral and transdermal 17 beta-estradiol combined with progesterone on homocysteine metabolism in postmenopausal women: A randomised placebo-controlled trial

Atherosclerosis

Volumn 174, Issue 1, 2004, Pages 173-180

  Lacut, Karine ^a,b   Oger, Emmanuel ^a   Abalain, Jean Hervé ^a   Moineau, Marie Pierre ^a   Mottier, Dominique ^c  

^a BREST UNIVERSITY HOSPITAL   (France)

^b SERVICE DE RHUMATOLOGIE   (France)

^c NONE

Author keywords

Folate; Homocysteine; Oral estrogen replacement therapy; Randomized controlled trial; Transdermal estrogen replacement therapy; Vitamin B12

Indexed keywords

CYANOCOBALAMIN; ESTRADIOL; HOMOCYSTEINE; PROGESTERONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ERYTHROCYTE; ESTROGEN THERAPY; FEMALE; FOLIC ACID BLOOD LEVEL; HEMOCONCENTRATION; HORMONE SUBSTITUTION; HUMAN; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; PATIENT SELECTION; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN METABOLISM; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; AGED; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ESTRADIOL; FEMALE; FOLLOW-UP STUDIES; HOMOCYSTEINE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PROBABILITY; PROGESTERONE; REFERENCE VALUES; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 2342596290     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2004.01.021     Document Type: Article

References (39)

1. Andersson A., Brattstrom L., Israelsson B., Isaksson A., Hamfelt A., Hultberg B. Plasma homocysteine before and after methionine loading with regard to age, gender, and menopausal status. Eur. J. Clin. Invest. 22:1992;79-87
2. Andersson A., Hultberg B., Brattstrom L., Isaksson A. Decreased serum homocysteine in pregnancy. Eur. J. Clin. Chem. Clin. Biochem. 30:1992;377-379
3. Wouters M.G., Moorrees M.T., van der Mooren M.J., et al. Plasma homocysteine and menopausal status. Eur. J. Clin. Invest. 25:1995;801-805
4. Hak A.E., Polderman K.H., Westendorp I.C., et al. Increased plasma homocysteine after menopause. Atherosclerosis. 149:2000;163-168
5. Anonymous. homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288:2015-22.
6. Klerk M., Verhoef P., Clarke R., Blom H.J., Kok F.J., Schouten E.G. MTHFR 677C → T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. 288:2002;2023-2031
7. Folsom A.R., Nieto F.J., McGovern P.G., et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 98:1998;204-210
8. Voutilainen S., Lakka T.A., Porkkala-Sarataho E., Rissanen T., Kaplan G.A., Salonen J.T. Low serum folate concentrations are associated with an excess incidence of acute coronary events: the Kuopio Ischaemic Heart Disease Risk Factor Study. Eur. J. Clin. Nutr. 54:2000;424-428
9. Voutilainen S., Rissanen T.H., Virtanen J., Lakka T.A., Salonen J.T. Low dietary folate intake is associated with an excess incidence of acute coronary events: The Kuopio Ischemic Heart Disease Risk Factor Study. Circulation. 103:2001;2674-2680
10. Ridker P.M., Hennekens C.H., Selhub J., Miletich J.P., Malinow M.R., Stampfer M.J. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation. 95:1997;1777-1782
11. Eichinger S., Stumpflen A., Hirschl M., et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb. Haemost. 80:1998;566-569
12. Ventura P., Cagnacci A., Malmusi S., et al. Continuous combined hormone replacement therapy with oral 17beta-estradiol and norethisterone acetate improves homocysteine metabolism in postmenopausal women. Menopause. 8:2001;252-258
13. Mijatovic V., Kenemans P., Jakobs C., van Baal W.M., Peters-Muller E.R., van der Mooren M.J. A randomized controlled study of the effects of 17beta-estradiol-dydrogesterone on plasma homocysteine in postmenopausal women. Obstet. Gynecol. 91:1998;432-436
14. Mijatovic V., Netelenbos C., van der Mooren M.J., de Valk-de Roo G.W., Jakobs C., Kenemans P. Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women. Fertil. Steril. 70:1998;1085-1089
15. van Baal W.M., Smolders R.G., van der Mooren M.J., Teerlink T., Kenemans P. Hormone replacement therapy and plasma homocysteine levels. Obstet. Gynecol. 94:1999;485-491
16. Barnabei V.M., Phillips T.M., Hsia J. Plasma homocysteine in women taking hormone replacement therapy: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. J. Womens Health Gend. Based Med. 8:1999;1167-1172
17. Walsh B.W., Paul S., Wild R.A., et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J. Clin. Endocrinol. Metab. 85:2000;214-218
18. Hak A.E., Bak A.A., Lindemans J., et al. The effect of hormone replacement therapy on serum homocysteine levels in perimenopausal women: a randomized controlled trial. Atherosclerosis. 158:2001;437-443
19. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 280:1998;605-613
20. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2003;288:321-33.
21. Evio S., Tiitinen A., Turpeinen U., Ylikorkala O. Failure of the combination of sequential oral and transdermal estradiol plus norethisterone acetate to affect plasma homocysteine levels. Fertil. Steril. 74:2000;1080-1083
22. Os I., Os A., Sandset P.M., et al. Hormone replacement therapy does not affect plasma homocysteine in postmenopausal women with coronary artery disease. Free tissue factor pathway inhibitor antigen, a circulating anticoagulant, is related to plasma homocysteine. Cardiology. 98:2002;6-12
23. Vigna G.B., Donega P., Zanca R., et al. Simvastatin, transdermal patch, and oral estrogen-progestogen preparation in early-postmenopausal hypercholesterolemic women: a randomized, placebo-controlled clinical trial. Metabolism. 51:2002;1463-1470
24. Giltay E.J., Verhoef P., Gooren L.J., et al. Otransdermal estrogens both lower plasma total homocysteine in male-to-female transsexuals. Atherosclerosis. 168:2003;139-146
25. Quere I., Perneger T.V., Zittoun J., et al. Red blood cell methylfolate and plasma homocysteine as risk factors for venous thromboembolism: a matched case-control study. Lancet. 359:2002;747-752
26. Oger E., Alhenc-Gelas M., Lacut K., et al. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women. A randomized trial. Arterioscler. Thromb. Vasc. Biol. 23:2003;1671-1676
27. Couturaud F., Oger E., Abalain J.H., et al. Methylenetetrahydrofolate reductase C677T genotype and venous thromboembolic disease. Respiration. 67:2000;657-661
28. Madsen J.S., Kristensen S.R., Klitgaard N.A., et al. Effect of long-term hormone replacement therapy on plasma homocysteine in postmenopausal women: a randomized controlled study. Am. J. Obstet. Gynecol. 187:2002;33-39
29. Berger P.B., Herrmann R.R., Dumesic D.A. The effect of estrogen replacement therapy on total plasma homocysteine in healthy postmenopausal women. Mayo. Clin. Proc. 75:2000;18-23
30. Carmel R., Howard J.M., Green R., et al. Hormone replacement therapy and cobalamin status in elderly women. Am. J. Clin. Nutr. 64:1996;856-859
31. Shojania A.M., Hornady G.J., Barnes P.H., et al. The effect of oral contraceptives on folate metabolism. Am. J. Obstet. Gynecol. 111:1971;782-791
32. Shojania A.M. Effect of oral contraceptives on vitamin-B12 metabolism. Lancet. 2:1971;932
33. Hjelt K., Brynskov J., Hippe E., Lundstrom P., Munck O. Oral contraceptives and the cobalamin (vitamin B12) metabolism. Acta Obstet. Gynecol. Scand. 64:1985;59-63
34. Wertalik L.F., Metz E.N., LoBuglio A.F., Balcerzak S.P. Decreased serum B 12 levels with oral contraceptive use. JAMA. 221:1972;1371-1374
35. Park J.S., Jung H.H., Yang W.S., Kim S.B., Min W.K., Chi H.S. Effects of hormonal replacement therapy on lipid and haemostatic factors in post-menopausal ESRD patients. Nephrol. Dial. Transplant. 15:2000;1835-1840
36. Tripodi A., Chantarangkul V., Lombardi R., Lecchi A., Mannucci P.M., Cattaneo M. for the ad hoc Study Group Multicenter study of homocysteine measurement - performance characteristics of different methods, influence of standards on interlaboratory agreement of results. Thromb. Haemost. 85:2001;291-295
37. Scarabin P.Y., Oger E., Plu-Bureau G., et al. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 362:2003;428-432
38. Lacut K., Oger E., Le Gal G., et al. Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein. Thromb. Haemost. 90:2003;124-131
39. Scarabin P.Y., Alhenc-Gelas M., Taisne P., Agher R., Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler. Thromb. Vasc. Biol. 17:1997;3071-3078